ArticleBlood advances2026
A biomarker risk assessment tool predicts infection-related mortality after allogeneic stem cell transplantation.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractNonrelapse mortality (NRM) in allogeneic haemopoietic stem cell transplantation (alloHSCT) is driven by acute graft-versus-host disease (aGVHD) and infection. The MAGIC algorithm probability (MAP) composite biomarker score is based on serum ST2 and REG3a levels at day (D)7 after transplantation and predicts aGVHD-related mortality. Although changes in MAP score predict aGVHD treatment response, their posttransplant predictive value and association with infection-related NRM (iNRM), independent of GVHD, are unclear. We evaluated the association of D0 to D21 MAP change (MAPΔ) vs D7 MAP with 6-month NRM (6mNRM) and developed a risk stratification model using random forest analysis and recursive partitioning. We prospectively enrolled 101 adult alloHSCT recipients from 2022 to 2024. Serum was collected weekly from D0 to D21 to derive MAPΔ. Associations with 6mNRM were assessed using generalized linear and random forest modeling. 6mNRM was 14.8%, with 80% (12/15) of deaths attributed to infection without prior aGVHD. Both MAPΔ ≥0.055 and D7 MAP ≥0.16 were significantly associated with 6mNRM (P< .0001), with MAPΔ showing superior predictive accuracy (receiver operator characteristic area under the curve 0.934 vs 0.779). In multivariable analysis, MAPΔ (odds ratio, 45; 95% confidence interval, 10.6-318; P = .01), but not D7 MAP, was an independent predictor of 6mNRM. A classification tree incorporating MAPΔ, D7 MAP, and age-adjusted comorbidity index stratified patients into low, intermediate, and high-risk groups. MAPΔ was a powerful, independent predictor of 6mNRM, which was driven by infection rather than aGVHD in this cohort. We propose a tool based on MAPΔ to assess iNRM, which may guide interventions and clinical trial design. Further validation in larger cohorts is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.